Print

Ariad Pharmaceuticals, Inc. (ARIA) Announces Initial Data on AP26113, Investigational Dual-Inhibitor of ALK and EGFR, to be Presented at the ESMO 2012 Congress of the European Society for Medical Oncology  
9/17/2012 9:38:12 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the initial data from its Phase 1/2 trial of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), will be presented at the ESMO 2012 Congress of the European Society for Medical Oncology (ESMO) being held in Vienna, Austria, September 28 to October 2, 2012.
//-->